DiaCarta Inc, Richmond, Virginia, USA.
Public Health, University of Naples Federico II, Naples, Italy.
J Clin Pathol. 2024 Jul 18;77(8):557-560. doi: 10.1136/jcp-2024-209527.
Cell-free DNA (cfDNA) has long been established as a useful diagnostic and prognostic tool in a variety of clinical settings, ranging from infectious to cardiovascular and neoplastic diseases. However, non-neoplastic diseases can act as confounders impacting on the amount of cfDNA shed in bloodstream and on technical feasibility of tumour derived free circulating nucleic acids selecting patients with cancer. Here, we investigated the potential impact of other pathological processes in the clinical stratification of 637 FIT+ patients. A single and multiple logistic regression yielded similar results. Crude sensitivity was 75.9% versus adjusted sensitivity of 74.1%, relative risk 0.9761 (0.8516 to 1.1188), risk difference 0.0181 (-0.0835 to 0.1199) and OR 0.9079 (0.5264 to 1.5658). Potential confounding effect from other source of cfDNA plays a pivotal role in the clinical stratification of FIT+ patients.
游离 DNA（cfDNA）在从感染到心血管和肿瘤疾病等多种临床环境中已被长期确立为一种有用的诊断和预后工具。然而，非肿瘤疾病可能会成为混杂因素，影响到在血液中释放的 cfDNA 的数量，以及肿瘤衍生的游离循环核酸选择癌症患者的技术可行性。在这里，我们研究了其他病理过程对 637 例 FIT+患者临床分层的潜在影响。单因素和多因素逻辑回归得到了相似的结果。未调整的敏感性为 75.9%，调整后的敏感性为 74.1%，相对风险为 0.9761（0.8516 至 1.1188），差异风险为 0.0181（-0.0835 至 0.1199），OR 为 0.9079（0.5264 至 1.5658）。来自其他 cfDNA 来源的潜在混杂效应在 FIT+患者的临床分层中起着关键作用。
